LU91512I2 - "Lacosamide et ses dérivés pharmaceutiquement acceptables (VIMPATr)" - Google Patents

"Lacosamide et ses dérivés pharmaceutiquement acceptables (VIMPATr)"

Info

Publication number
LU91512I2
LU91512I2 LU91512C LU91512C LU91512I2 LU 91512 I2 LU91512 I2 LU 91512I2 LU 91512 C LU91512 C LU 91512C LU 91512 C LU91512 C LU 91512C LU 91512 I2 LU91512 I2 LU 91512I2
Authority
LU
Luxembourg
Prior art keywords
lower alkyl
aryl
heterocyclic
unsubstituted
substituted
Prior art date
Application number
LU91512C
Other languages
English (en)
Original Assignee
Res Corp Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Tech Inc filed Critical Res Corp Tech Inc
Publication of LU91512I2 publication Critical patent/LU91512I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU91512C 2000-08-25 2009-01-14 "Lacosamide et ses dérivés pharmaceutiquement acceptables (VIMPATr)" LU91512I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22823000P 2000-08-25 2000-08-25
PCT/US2001/026568 WO2002015922A2 (fr) 2000-08-25 2001-08-24 Nouvelles utilisations d'anticonvulsivants a base d'acides amines

Publications (1)

Publication Number Publication Date
LU91512I2 true LU91512I2 (fr) 2009-03-16

Family

ID=22856332

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91512C LU91512I2 (fr) 2000-08-25 2009-01-14 "Lacosamide et ses dérivés pharmaceutiquement acceptables (VIMPATr)"

Country Status (13)

Country Link
US (6) US6884910B2 (fr)
EP (5) EP1365787B1 (fr)
JP (2) JP4307068B2 (fr)
AT (4) ATE357227T1 (fr)
AU (6) AU2001286763C1 (fr)
CA (2) CA2740815C (fr)
CY (5) CY1107668T1 (fr)
DE (4) DE60142806D1 (fr)
DK (4) DK1486206T3 (fr)
ES (5) ES2281439T3 (fr)
LU (1) LU91512I2 (fr)
PT (4) PT1486205E (fr)
WO (1) WO2002015922A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60142806D1 (de) * 2000-08-25 2010-09-23 Res Corp Technologies Inc Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
EP1243262B1 (fr) 2001-03-20 2006-05-31 Schwarz Pharma Ag Nouvelle utilisation d'un composé peptidique pour le traitement de la douleur inflammatoire non-neuropathique
EP1243263B1 (fr) * 2001-03-21 2002-11-27 Schwarz Pharma Ag Nouvelle utilisation d'une classe de composés peptidiques pour le traitement de l'allodynie ou d'autres types de douleurs chroniques ou fantômes
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20050233472A1 (en) * 2003-09-19 2005-10-20 Kao H P Spotting high density plate using a banded format
EP1537862A1 (fr) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la douleur neuropathique centrale
AU2004294714B2 (en) * 2003-12-02 2009-12-10 Ucb Pharma Gmbh Novel use of peptide compounds for treating central neuropathic pain
EP1579858A1 (fr) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
MXPA06011937A (es) 2004-04-16 2007-01-26 Sanol Arznei Schwarz Gmbh Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico.
EP1604654A1 (fr) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604655A1 (fr) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1629839A1 (fr) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Utilisation de composés peptidiques pour le traitement de douleurs liées au cancer des os et des douleurs induites par la chimiothérapie ou des nucléosides
BRPI0514721A (pt) 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (fr) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (fr) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité
SI2462990T1 (sl) * 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
US7489198B1 (en) 2007-04-26 2009-02-10 Lockheed Martin Corporation Linear regulating switch
WO2011101863A2 (fr) 2010-02-19 2011-08-25 Cadila Healthcare Limited Compositions pharmaceutiques à libération prolongée de lacosamide
WO2015200322A1 (fr) * 2014-06-23 2015-12-30 Northwestern University Procédés de traitement ou de soulagement de la migraine
WO2017079169A1 (fr) 2015-11-03 2017-05-11 Kimberly-Clark Worldwide, Inc. Mouchoir en papier à volume élevé et peu pelucheux
WO2019108172A1 (fr) 2017-11-29 2019-06-06 Kimberly-Clark Worldwide, Inc. Feuille fibreuse ayant des propriétés améliorées
BR112021001335B1 (pt) 2018-07-25 2024-03-05 Kimberly-Clark Worldwide, Inc Método para fazer um substrato absorvente não tecido tridimensional (3d)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
FR2546517B1 (fr) * 1983-05-24 1987-04-24 Panmedica Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5178729A (en) * 1991-01-15 1993-01-12 James River Corporation Of Virginia High purity stratified tissue and method of making same
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
AU5890394A (en) 1993-02-03 1994-08-29 Steven Andrew Jennings Blends of glycine derivatives and sugars
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
EP0784629B1 (fr) * 1994-10-05 1999-04-28 Darwin Discovery Limited Composes de peptidyle et leur usage therapeutique en tant qu'inhibiteurs des metalloproteases
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
KR100522012B1 (ko) 1997-07-08 2005-10-18 오노 야꾸힝 고교 가부시키가이샤 아미노산 유도체
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
AU744899B2 (en) 1997-07-15 2002-03-07 Research Corporation Technologies, Inc. Amino acid derivatives useful to treat stroke
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
RU2219924C2 (ru) * 1998-04-14 2003-12-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения нейропсихиатрических расстройств
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6399574B1 (en) * 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
DE60142806D1 (de) 2000-08-25 2010-09-23 Res Corp Technologies Inc Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
US6228825B1 (en) 2000-10-13 2001-05-08 Colgate Palmolive Company Automatic dishwashing cleaning system
EP1243262B1 (fr) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Nouvelle utilisation d'un composé peptidique pour le traitement de la douleur inflammatoire non-neuropathique

Also Published As

Publication number Publication date
PT1365787E (pt) 2007-06-29
US20130316953A1 (en) 2013-11-28
PT1486205E (pt) 2008-01-25
US20040097416A1 (en) 2004-05-20
JP2009108090A (ja) 2009-05-21
JP2004506692A (ja) 2004-03-04
US6884910B2 (en) 2005-04-26
WO2002015922A3 (fr) 2003-09-25
CY1107668T1 (el) 2010-07-28
EP1365787A2 (fr) 2003-12-03
DK1365787T3 (da) 2007-07-23
PT1486206E (pt) 2008-01-25
EP2210598B1 (fr) 2013-09-18
CY2009002I2 (el) 2009-11-04
CY1107853T1 (el) 2013-06-19
PT1695703E (pt) 2010-11-16
ATE357227T1 (de) 2007-04-15
CY1112349T1 (el) 2015-12-09
WO2002015922A2 (fr) 2002-02-28
AU2007202336B2 (en) 2009-09-24
DE60131032T2 (de) 2008-08-14
CA2419285C (fr) 2011-08-02
EP1486205A1 (fr) 2004-12-15
US7148378B2 (en) 2006-12-12
AU2007202336B9 (en) 2009-10-29
EP1695703A3 (fr) 2006-12-13
ES2348646T3 (es) 2010-12-10
DE60127459T2 (de) 2007-07-12
EP1486206B1 (fr) 2007-10-17
US20100273716A1 (en) 2010-10-28
DE60127459D1 (de) 2007-05-03
ATE375792T1 (de) 2007-11-15
CY1107852T1 (el) 2013-06-19
AU2001286763B2 (en) 2005-11-24
AU2007202336A1 (en) 2007-06-14
CA2740815C (fr) 2014-03-18
DE60131033T2 (de) 2008-07-17
AU2001286763C1 (en) 2006-03-02
DK1486205T3 (da) 2008-02-18
DK1695703T3 (da) 2010-10-25
US7186859B2 (en) 2007-03-06
CY2009002I1 (el) 2009-11-04
US20070142297A1 (en) 2007-06-21
AU2009202363B2 (en) 2011-02-17
AU8676301A (en) 2002-03-04
AU2009202362B2 (en) 2011-01-27
DE60131033D1 (de) 2007-11-29
US20040087508A1 (en) 2004-05-06
AU2009202362A1 (en) 2009-07-02
US8519183B2 (en) 2013-08-27
CA2740815A1 (fr) 2002-02-28
ES2294414T3 (es) 2008-04-01
EP2210598A2 (fr) 2010-07-28
ES2294415T3 (es) 2008-04-01
EP1365787B1 (fr) 2007-03-21
US7772427B2 (en) 2010-08-10
ES2435000T3 (es) 2013-12-18
AU2009202363A1 (en) 2009-07-02
AU2011202293A1 (en) 2011-06-09
JP5190334B2 (ja) 2013-04-24
ES2281439T3 (es) 2007-10-01
ATE476971T1 (de) 2010-08-15
DE60142806D1 (de) 2010-09-23
US20020086828A1 (en) 2002-07-04
DK1486206T3 (da) 2008-02-11
ATE375793T1 (de) 2007-11-15
EP1486206A1 (fr) 2004-12-15
EP1695703A2 (fr) 2006-08-30
AU2011202293B2 (en) 2013-01-10
EP1695703B1 (fr) 2010-08-11
EP1486205B1 (fr) 2007-10-17
CA2419285A1 (fr) 2002-02-28
DE60131032D1 (de) 2007-11-29
EP2210598A3 (fr) 2011-07-20
JP4307068B2 (ja) 2009-08-05

Similar Documents

Publication Publication Date Title
LU91512I2 (fr) "Lacosamide et ses dérivés pharmaceutiquement acceptables (VIMPATr)"
JP2007530493A5 (fr)
JP2008501760A5 (fr)
JP2008501753A5 (fr)
JP2008510758A5 (fr)
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
JP2008503533A5 (fr)
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
EA200500583A1 (ru) Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
NO20032510L (no) Organiske forbindelser
NO943879D0 (no) Hemming av endometriose
KR950010892A (ko) 자궁 섬유증 억제 방법
NO943875D0 (no) Hemming av angiogenese og angiogene sykdommer
DK0659411T3 (da) Fremgangsmåde til forøgelse af libido hos kvinder efter menopausen
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
NO944917L (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av ovarial dysgenese, forsinket pubertet eller seksuell infantilisme
RU2005122323A (ru) Производные бензамида в качестве агонистов окситоцина и антагонистов вазопрессина
KR950016720A (ko) 아밀로이드 단백질의 효과를 저해하는 방법
TR200103562T2 (tr) Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
KR970706819A (ko) 브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin)
RU2003103757A (ru) Жидкая лекарственная форма налтрексона
RU2002133285A (ru) Средство для регуляции репродуктивной функции и половой активности позвоночных животных и способ регуляции репродуктивной функции и половой активности позвоночных животных
TH23898A (th) วิธีการหยุดยั้งการออกฤทธิ์ของ il-6